Baricinitib reduction after achieving remission may keep remission in RA patients

Baricinitib reduction after achieving remission may keep remission in RA patients - BREAK study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037514

Enrollment

Registered

2019-08-01

Start date

2019-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with rheumatoid arthritis over 20 years old who fulfills ACR/EULAR criteria and treated by 4mg/day baricitinib

Exclusion criteria

Exclusion criteria: Those who were considered not suitable for the study by researchers

Design outcomes

Primary

Measure	Time frame
risk factors for flare after baricitinib reduction	—

Countries

Japan

Contacts

Public ContactTadashi Okano

Osaka city university Orthopedics

seikei@med.osaka-cu.ac.jp0666453851

Outcome results